. 2014 Jul 20;2014:540309. doi: 10.1155/2014/540309

Table 1.

Characteristics of studies included in the meta-analysis.

Study	Year	Country	Ethnicity	Cancer type	Source of controls	Genotype methods	Genotype (case/control)				HWE
Study	Year	Country	Ethnicity	Cancer type	Source of controls	Genotype methods	Total	WT Ho	Ht	VR Ho	(P value)
HSP70-2								AA	AG	GG

Chouchane et al. [11]	1997a	Tunisia	African	Non-Hodgkin's lymphoma	PB	AFLP	44/106	4/22	28/82	12/2	0
Chouchane et al. [11]	1997b	Tunisia	African	Breast	PB	AFLP	40/106	4/22	26/82	10/2	0
Ferrer-Ferrer et al. [12]	2013	Costa Rica	Mixed	Gastric	HB	RFLP	39/79	7/30	26/32	6/17	0.137
Jalbout et al. [14]	2003	Tunisia	African	Nasopharyngeal	PB	AFLP	140/274	40/101	68/138	32/35	0.251
Jeng et al. [15]	2008	Taiwan (China)	Asian	Hepatocellular	HB	AFLP	150/150	28/70	55/65	67/15	0.987
Kádár et al. [16]	2008	Hungary	European	Multiple myeloma	PB	PCR-RFLP	94/141	34/65	60/76∗		NA
Li et al. [17]	2010	China	Asian	Hepatocellular	HB	PCR	145/127	48/56	71/62	26/9	0.139
Medhi et al. [18]	2013	India	Asian	Hepatocellular	PB	PCR-RFLP	185/200	111/156	59/40	15/4	0.453
Mestiri et al. [19]	2001	Tunisia	African	Breast	PB	PCR	243/174	52/35	123/130	68/9	0
Rehman et al. [20]	2009	India	Aisian	Kangri cancer	PB	PCR-RFLP	118/95	10/24	103/70	5/1	0
Shibata et al. [23]	2009	Japan	Asian	Gastric	HB	PCR-RFLP	225/200	46/33	173/155	6/12	0
Srivastava et al. [24]	2012	India	Asian	Pancreatic	PB	PCR-RFLP	50/50	13/33	29/15	8/2	0.858
Tóth et al. [25]	2007	Hungary	European	Colorectal	PB	PCR-RFLP	183/141	69/65	87/57	27/19	0.258
Ucisik-Akkaya et al. [26]	2010a	UK	European	Childhood ALL	PB	PCR-RFLP	114/414	58/139	47/199	9/76	0.747
Ucisik-Akkaya et al. [26]	2010b	Mexico	Mixed	Childhood ALL	PB	PCR-RFLP	92/235	27/61	51/111	14/63	0.397
Wang et al. [27]	2010	China	Asian	Lung	HB	PCR-RFLP	159/202	57/56	72/100	30/46	0.915
Zagouri et al. [28]	2012	Greece	European	Breast	HB	PCR	113/124	24/32	82/76	7/16	0.006

HSP70-hom								TT	TC	CC

Chouchane et al. [11]	1997a	Tunisia	African	Non-Hodgkin's lymphoma	PB	AFLP	44/106	31/98	10/8	3/0	0.686
Chouchane et al. [11]	1997b	Tunisia	African	Breast	PB	AFLP	40/106	31/98	8/8	1/0	0.686
Ferrer-Ferrer et al. [12]	2013	Costa Rica	Mixed	Gastric	HB	RFLP	39/79	34/55	5/23	0/1	0.409
Guo et al. [13]	2011	China	Asian	Lung	PB	TaqMan	1152/1152	674/695	412/411	66/46	0.124
Medhi et al. [18]	2013	India	Asian	Hepatocellular	PB	PCR-RFLP	185/200	178/144	7/42	0/14	0.0001
Rehman et al. [20]	2009	India	Aisian	Kangri cancer	PB	PCR-RFLP	118/95	60/28	56/60	2/7	0.001
Sfar et al. [22]	2010	Tunisia	African	Prostate	PB	PCR-RFLP	101/105	77/65	20/32	4/8	0.164
Ucisik-Akkaya et al. [26]	2010a	UK	European	Childhood ALL	PB	TaqMan	105/371	67/246	30/103	8/22	0.015
Ucisik-Akkaya et al. [26]	2010b	Mexico	Mixed	Childhood ALL	PB	TaqMan	99/245	87/214	11/27	1/4	0.008
Wang et al. [27]	2010	China	Asian	Lung	HB	PCR-RFLP	159/202	95/141	56/59	8/2	0.120

HSP70-1								GG	GC	CC

Guo et al. [13]	2011	China	Asian	Lung	PB	TaqMan	1152/1152	589/564	457/486	106/102	0.853
Partida-Rodríguez et al. [21]	2010	Mexico	Mixed	Gastric	HB	PCR-RFLP	42/106	4/59	37/41	1/6	0.746
Ucisik-Akkaya et al. [26]	2010a	UK	European	Childhood ALL	PB	TaqMan	106/365	47/137	45/162	14/66	0.139
Ucisik-Akkaya et al. [26]	2010b	Mexico	Mixed	Childhood ALL	PB	TaqMan	99/250	62/127	32/98	5/25	0.347
Wang et al. [27]	2010	China	Asian	Lung	HB	PCR-RFLP	159/202	57/104	65/82	37/16	0.977

HWE, Hardy-Weinberg equilibrium; P _HWE was calculated by goodness-of fit χ ²-test, P _HWE < 0.05 was considered statistically significant; NA, not available. Ht, heterozygote; VR Ho, variant homozygote; WT Ho, wide-type homozygote; ∗Numbers of Ht + VR Ho.